Department of Thoracic Surgery, Yedikule Chest Diseases, Thoracic Surgery Training and Research Hospital, SUAM Zeytinburnu/İST, 34188, Istanbul, Turkey.
Thoracic Surgery, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Gen Thorac Cardiovasc Surg. 2021 May;69(5):823-831. doi: 10.1007/s11748-020-01545-6. Epub 2020 Nov 13.
Carinal and main bronchus involvement were compared in terms of the survival of patients with N0-1 non-small cell lung cancer (NSCLC).
Sixty-six NSCLC patients who underwent complete surgical carinal resection/reconstruction (Carina group) and complete resection because of main bronchus involvement (Main Bronchus group) between 2006 and 2016 were retrospectively analyzed. The Carina group included 30 patients and the Main Bronchus group included 36. In the Carina group, conditions other than carinal involvement that rendered patients pathological (p) T4, and in the Main Bronchus group, conditions that would upstage the pT status from pT2 were excluded. Patients with mediastinal lymph node metastases were excluded. Thus, an isolated main bronchial invasion and isolated carinal invasion patient population was tried to be obtained.
The overall 5-year survival rate was 49.4% (median 61.5 ± 19.9 months). The 5-year survival rates of patients in the Carina group was 49.2% (median 63.3 months), and that of patients in the Main Bronchus group was 46.4% (median 55.9 months). The difference between survival rates was not statistically significant (p = 0.761). The survival rates of pN0 and pN1 patients also did not differ significantly (63.2% vs. 45.5%, p = 0.207). Recurrence was significantly more common in the Main Bronchus group than the Carina group (28.1% vs. 7.1%; p = 0.04).
Isolated carinal invasion had a comparable outcome to isolated main bronchus invasion in pN0-1 patients with NSCLC who are undergoing anatomical surgical resection.
比较 N0-1 期非小细胞肺癌(NSCLC)患者发生隆突和主支气管侵犯时的生存情况。
回顾性分析 2006 年至 2016 年间行完全隆突切除/重建(隆突组)和因主支气管受累而行完全切除(主支气管组)的 66 例 NSCLC 患者。隆突组 30 例,主支气管组 36 例。在隆突组中,排除除隆突受累以外的其他条件导致患者病理分期(p)为 T4,在主支气管组中,排除将 pT 分期升级为 pT2 的其他条件。排除纵隔淋巴结转移的患者。因此,试图获得孤立性主支气管侵犯和孤立性隆突侵犯患者人群。
总体 5 年生存率为 49.4%(中位 61.5±19.9 个月)。隆突组患者的 5 年生存率为 49.2%(中位 63.3 个月),主支气管组为 46.4%(中位 55.9 个月)。两组生存率差异无统计学意义(p=0.761)。pN0 和 pN1 患者的生存率也无显著差异(63.2% vs. 45.5%,p=0.207)。主支气管组的复发率明显高于隆突组(28.1% vs. 7.1%;p=0.04)。
在行解剖性手术切除的 pN0-1 NSCLC 患者中,孤立性隆突侵犯与孤立性主支气管侵犯的结果相当。